Objective: Different studies have indicated that the Resperidon alleviates the general signs of schizophrenics more than Haloperidol. Since there have not been such researche in Iranian populations, we to compared the efficacy of Resperidon (Iran made) and Haloperidol in reducing the general signs of schizophrenia.

Materials & Methods: Frothy five schizophrenic patients (based on DSM-IV criteria) who had been admitted in Razi Psychiatric Center were studied in a before – after experimental study. After a 2-week washout period the patients were randomly assigned into Haloperidol (15mg/d) and Resperidon (6mg/d) groups. For each patient the general subscale of Brief Psychiatric Rating Scale (BPRS) and extra pyramidal complication scales were evaluated and recorded at baseline examination weekly for 8 weeks, after initiation of the therapy. The results were analyzed using t-test for paired samples, independent samples t-test and general linear model (GLM) repeated measured as the main variable, two therapeutic methods between subject factor and timing within subject factor in analysis.

Results: No significant differences were observe between the mean score of general signs in baseline until fifth week of treatment course (P>0.05). From the sixth week till the end of the study the mean score of general signs were significantly lower in Resperidon group compared to Haloperidol group (P<0.05). Both drug was resulted in mean general score reduction. The pattern of mean general score reduction had a significant difference between two goups and the intensity of complications were significantly lower in patients receiving Resperidon compared with Haloperidol group (P<0.05).

Conclusion: Prescription of both Iran made Resperidon and Haloperidol reduce general signs of Iranian schizophrenic patients and Resperidon had significantly better effects in this Reducation. The side effects of Resperidon were significantly lower than Haloperidol.